This study demonstrated the feasibility of using EVs to deliver exogenous mRNA to tumors to induce tumor immune response to treat HER2+ breast cancer, setting the stage for engineered EVs to be used for other cancer immunotherapy targets. This evidence concerns the gene ERBB2 and neoplasm.